TY - JOUR
T1 - Nanotherapeutics and Nanotheragnostics for Cancers
T2 - Properties, Pharmacokinetics, Biopharmaceutics, and Biosafety
AU - Morsink, Margreet
AU - Parente, Lucia
AU - Silva, Fernanda
AU - Abrantes, Alexandra
AU - Ramos, Ana
AU - Primo, Inês
AU - Willemen, Niels
AU - Sanchez-Lopez, Elena
AU - Severino, Patricia
AU - Souto, Eliana B.
N1 - Funding Information:
The study was funded by Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/ COMPETE) for the projects M-ERA-NET/0004/2015-PAIRED and UIDB/04469/2020 (strategic fund), co-financed by FEDER, under the Partnership Agreement PT2020.
Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - With the increasing worldwide rate of chronic diseases, such as cancer, the development of novel techniques to improve the efficacy of therapeutic agents is highly demanded. Nanoparticles are especially well suited to encapsulate drugs and other therapeutic agents, bringing additional advantages, such as less frequent dosage requirements, reduced side effects due to specific targeting, and therefore increased patient compliance. However, with the increasing use of nanoparticles and their recent launch on the pharmaceutical market, it is important to achieve high-quality control of these advanced systems. In this review, we discuss the properties of different nanoparticles, the pharmacokinetics, the biosafety issues of concern, and conclude with novel nanotherapeutics and nanotheragnostics for cancer drug delivery.
AB - With the increasing worldwide rate of chronic diseases, such as cancer, the development of novel techniques to improve the efficacy of therapeutic agents is highly demanded. Nanoparticles are especially well suited to encapsulate drugs and other therapeutic agents, bringing additional advantages, such as less frequent dosage requirements, reduced side effects due to specific targeting, and therefore increased patient compliance. However, with the increasing use of nanoparticles and their recent launch on the pharmaceutical market, it is important to achieve high-quality control of these advanced systems. In this review, we discuss the properties of different nanoparticles, the pharmacokinetics, the biosafety issues of concern, and conclude with novel nanotherapeutics and nanotheragnostics for cancer drug delivery.
KW - Advanced drug delivery
KW - Cancer drug delivery
KW - Cancer nanotheragnostics
KW - Drug nanoparticles
KW - Nanomedicine
KW - Nanosafety
KW - Nanotheragnostics
KW - Nanotherapeutics
KW - Pharmacokinetics
KW - NLA
UR - http://www.scopus.com/inward/record.url?scp=85122228315&partnerID=8YFLogxK
U2 - 10.2174/1381612827666210804102645
DO - 10.2174/1381612827666210804102645
M3 - Review article
C2 - 34348617
SN - 1381-6128
VL - 28
SP - 104
EP - 115
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 2
ER -
